Investor List:

Top Diagnostics Series B Investors in Boston / New England (34)

Know someone who's actively diligencing and investing? Add them to this list.
About this list
We’ve compiled a list of the top Diagnostics investors. The goal is to help Founders find the best investors to target and get introduced to.
Photo of Geoffrey Smith, Managing Partner at Digitalis Ventures
Geoffrey Smith
Digitalis Ventures·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in New York (NY), Investors in Los Angeles (CA), Investors in San Francisco (CA), Investors in Boston (MA)
Investors in Diagnostics (Series A), Investors in Diagnostics (Series B), Investors in Therapeutics (Series B), Investors in Diagnostics (Seed), Investors in Therapeutics (Series A), Investors in Diagnostics (Series A), Investors in Therapeutics (Seed), Investors in Diagnostics (Seed), Investors in Diagnostics (Series A), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Diagnostics (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Series B), Investors in Diagnostics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Diagnostics (Seed), Investors in Diagnostics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Diagnostics (Seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A), Investors in Diagnostics (Seed), Investors in Manufacturing (Series B), Investors in Manufacturing (Series B), Investors in BioTech (Series B), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Digital Health (Series B), Investors in Manufacturing (Series A), Investors in Manufacturing (Series B), Investors in Digital Health (Series B), Investors in BioTech (Series A), Investors in Manufacturing (Series A), Investors in Manufacturing (Seed), Investors in BioTech (Series B), Investors in Digital Health (Series A), Investors in Manufacturing (Seed), Investors in Health IT (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Series B), Investors in Manufacturing (Series A), Investors in Manufacturing (Seed), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series A), Investors in Manufacturing (Series B), Investors in BioTech (Series B), Investors in Digital Health (Series B), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series A), Investors in BioTech (Seed), Investors in Health & Hospital Services (Series A), Investors in Digital Health (Seed), Investors in BioTech (Series A), Investors in Manufacturing (Series B), Investors in Health & Hospital Services (Seed), Investors in Health IT (Series A), Investors in Manufacturing (Series A), Investors in BioTech (Series A), Investors in Health IT (Seed), Investors in Health & Hospital Services (Seed), Investors in Health & Hospital Services (Series B), Investors in BioTech (Seed), Investors in Health IT (Series B), Investors in Health IT (Seed), Investors in Digital Health (Series A), Investors in Manufacturing (Seed), Investors in Manufacturing (Series A), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Digital Health (Series B), Investors in Manufacturing (Seed), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Digital Health (Series A), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Digital Health (Seed), Investors in Digital Health (Series B), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in BioTech (Series B), Investors in Digital Health (Series A), Investors in BioTech (Series A), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in Health IT (Series A), Investors in BioTech (Series A), Investors in Health IT (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Seed), Investors in Health IT (Series A), Investors in Health IT (Seed), Investors in Los Angeles / Southern California (Other Lists), Investors in Boston / New England (Other Lists), Investors in New York City (Other Lists), Investors in San Francisco Bay Area (Other Lists)
Photo of Cris De Luca, Partner at Sanofi Ventures
Cris De Luca
Sweet spot: $7.5M
Range: $5.0M - $10.0M
Investors in Paris (France), Investors in Israel, Investors in New York (NY), Investors in Europe, Investors in San Francisco (CA), Investors in Cambridge (MA)
Investors in Pharmaceuticals (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Series B), Investors in Pharmaceuticals (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series B), Investors in Medical Devices (Series B), Investors in Diagnostics (Series B), Investors in Medical Devices (Series B), Investors in Consumer Health (Series B), Investors in AR/VR (Series B), Investors in Medical Devices (Series A), Investors in AR/VR (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Series B), Investors in Health IT (Series B), Investors in Medical Devices (Series B), Investors in Digital Health (Series B), Investors in Medical Devices (Series A), Investors in Diagnostics (Series B), Investors in Pharmaceuticals (Series B), Investors in IoT (Series B), Investors in AR/VR (Series A), Investors in AR/VR (Series A), Investors in Pharmaceuticals (Series B), Investors in Diagnostics (Series A), Investors in Medical Devices (Series B), Investors in AR/VR (Series B), Investors in Consumer Health (Series B), Investors in Diagnostics (Series A), Investors in Digital Health (Series A), Investors in Medical Devices (Series A), Investors in Pharmaceuticals (Series A), Investors in IoT (Series B), Investors in IoT (Series A), Investors in Health IT (Series A), Investors in Pharmaceuticals (Series B), Investors in Consumer Health (Series A), Investors in AR/VR (Series A), Investors in AR/VR (Series B), Investors in Pharmaceuticals (Series A), Investors in IoT (Series B), Investors in Digital Health (Series B), Investors in Consumer Health (Series A), Investors in IoT (Series A), Investors in AI (Series B), Investors in Consumer Health (Series B), Investors in Medical Devices (Series A), Investors in Health IT (Series B), Investors in Digital Health (Series A), Investors in IoT (Series A), Investors in Medical Devices (Series B), Investors in Pharmaceuticals (Series A), Investors in Digital Health (Series B), Investors in IoT (Series B), Investors in AI (Series B), Investors in Pharmaceuticals (Series B), Investors in AR/VR (Series A), Investors in Health IT (Series A), Investors in AR/VR (Series B), Investors in Consumer Health (Series B), Investors in AI (Series A), Investors in Health IT (Series B), Investors in Digital Health (Series B), Investors in Consumer Health (Series A), Investors in Digital Health (Series A), Investors in AI (Series A), Investors in Medical Devices (Series A), Investors in AI (Series B), Investors in IoT (Series A), Investors in Consumer Health (Series B), Investors in IoT (Series B), Investors in Pharmaceuticals (Series A), Investors in AR/VR (Series A), Investors in Digital Health (Series A), Investors in Health IT (Series B), Investors in Consumer Health (Series A), Investors in Health IT (Series A), Investors in AI (Series A), Investors in Israel (Other Lists), Investors in Digital Health (Series B), Investors in AI (Series B), Investors in IoT (Series A), Investors in Consumer Health (Series A), Investors in Health IT (Series A), Investors in Health IT (Series B), Investors in Digital Health (Series A), Investors in Diverse Investors (Other Lists), Investors in Boston / New England (Other Lists), Investors in Investors who were founders (Other Lists), Investors in AI (Series A), Investors in AI (Series B), Investors in Investors who invested in female founders (Other Lists), Investors in Investors who invested in diverse founders (Other Lists), Investors in Health IT (Series A), Investors in New York City (Other Lists), Investors in AI (Series A), Investors in San Francisco Bay Area (Other Lists)
Photo of Jon Lim, Partner at F-Prime Capital Partners
Jon Lim
Sweet spot: $5.0M
Range: $100K - $10.0M
Investors in Boston (MA)
Photo of Jennifer Levin Carter, Managing Director at Sandbox Industries
Jennifer Levin Carter
Sandbox Industries·Managing Director
Sweet spot: $10.5M
Range: $1M - $20.0M
Investors in Boston (MA)
Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Seed), Investors in Diagnostics (Series A), Investors in Diagnostics (Series B), Investors in AI (Series B), Investors in Health IT (Series B), Investors in Digital Health (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in BioTech (Series B), Investors in Diagnostics (Seed), Investors in Health & Hospital Services (Series B), Investors in AI (Series A), Investors in Health & Hospital Services (Series A), Investors in AI (Seed), Investors in Health IT (Series A), Investors in Health & Hospital Services (Seed), Investors in BioTech (Series A), Investors in Health IT (Seed), Investors in BioTech (Seed), Investors in BioTech (Series B), Investors in Digital Health (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in AI (Series B), Investors in Digital Health (Series A), Investors in BioTech (Series A), Investors in Boston / New England (Other Lists), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Seed), Investors in Digital Health (Seed), Investors in Health IT (Seed), Investors in BioTech (Seed), Investors in AI (Series A), Investors in AI (Seed)
Photo of Jonathan Gertler, Managing Director at BioVentures Investors
Jonathan Gertler
BioVentures Investors·Managing Director
Sweet spot: $10.0M
Range: $5.0M - $25.0M
Investors in Boston (MA)
Photo of Andrew Hack, Managing Director at Bain Capital Life Sciences
Andrew Hack
Bain Capital Life Sciences·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Boston (MA)
Investors in Diagnostics (Series A), Investors in Diagnostics (Series B), Investors in Diagnostics (Seed), Investors in Medical Devices (Series B), Investors in Diagnostics (Series B), Investors in Medical Devices (Series A), Investors in Pharmaceuticals (Series B), Investors in Medical Devices (Seed), Investors in Diagnostics (Series A), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Seed), Investors in Medical Devices (Series B), Investors in BioTech (Series B), Investors in Diagnostics (Seed), Investors in Pharmaceuticals (Series B), Investors in Boston / New England (Other Lists), Investors in BioTech (Series A), Investors in Medical Devices (Seed), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series A), Investors in Medical Devices (Series A), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in BioTech (Series A), Investors in BioTech (Seed)
Photo of Jeffrey Barnes, General Partner at BioVentures Investors
Jeffrey Barnes
BioVentures Investors·General Partner
Sweet spot: $10.0M
Range: $5.0M - $25.0M
Investors in Boston (MA)
Investors in Diagnostics (Seed), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Medical Devices (Series B), Investors in Medical Devices (Series A), Investors in Diagnostics (Series B), Investors in Medical Devices (Seed), Investors in Diagnostics (Series A), Investors in Diagnostics (Seed), Investors in BioTech (Series B), Investors in Medical Devices (Series B), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in Medical Devices (Series A), Investors in Medical Devices (Seed), Investors in BioTech (Series B), Investors in Boston / New England (Other Lists), Investors in BioTech (Seed), Investors in BioTech (Series A)
Photo of David Averett, Managing Director at Summit Partners
David Averett
Summit Partners·Managing Director
Sweet spot: $20.0M
Range: $5.0M - $50.0M
Investors in Boston (MA)